Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05994729
Other study ID # AH Card. 08-23
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 1, 2024
Est. completion date December 31, 2026

Study information

Verified date October 2023
Source Aurelia Hospital
Contact Fabrizio Tomai, MD, FACC, FESC
Phone 0039 06 65975725
Email fabriziotomai@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Long-standing hypertension may cause an impairment in microvascular coronary circulation which is involved in many different cardiac conditions. Renal denervation (RDN) has been successfully proven as a valuable and powerful therapeutic choice to consider for patients with resistant hypertension; moreover this procedure looks promising in other cardiac disease such as heart failure and atrial fibrillation, given its ability to downregulate sympathetic nervous system The aim of this study is to explore the effect of renal denervation and blood pressure control on coronary microvascular dysfunction. This is a multicenter, prospective, non randomized, open-label, interventional study. Consecutive patients with resistant hypertension, non obstructive coronary artery disease and documented microvascular dysfunction will be enrolled. Patients will undergo renal denervation by Spyral Symplicity 3 and re-assessment of coronary microvascular function 12 months after the procedure. Primary endpoint will be the difference in average index of microcirculatory resistance value.


Description:

The aim of this study is to evaluate the effect of radiofrequency RDN performed with Spyral Symplicity 3 on microvascular function in patients with ascertained hypertension related coronary microvascular dysfunction (hy-CMD) and/or hypertensive cardiomyopathy. Our hypothesis is that RDN could improve invasive parameters of microvascular function in patients with hy-CMD; these would mean that RDN would be able to at least partially revert the pathogenesis of hy-CMD. The study design comprises an initial rule-in and enrollment phase, required to properly select the target population, followed by the actual study procedural phase. Patients amenable to RDN will be hospitalized and enter the rule-in phase to check for eligibility. Before performing the actual RDN, patients will be asked for the written informed consent to receive physiological evaluation. Only patients that will be diagnosed with hy-CMD will eventually enter the actual study phase. This phase will comprise repeated outpatients visits, according to a predetermined schedule, including a new hospitalization at 12 months to reassess coronary microvascular physiology.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 87
Est. completion date December 31, 2026
Est. primary completion date January 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Rul-in Phase Inclusion Criteria: - Non obstructive stable coronary artery disease (CAD) on invasive coronary angiography (defined as the absence of either >50% angiographic stenosis or any flow limiting lesion on functional evaluation) - Suspected diagnosis of difficult to control/ resistant hypertension for which renal denervation by radiofrequency ablation with Spyral Symplicity 3 could be considered. Rule-in Phase Exclusion Criteria: - Initiation of either nitrates, beta-blocker or calcium channel blocker less than 30 days before the end of the rule-in phase - Physiological assessment performed during first medical contact documenting preserved coronary microvascular function - Physiological assessment performed at the "first contact" hospitalization followed by modification of medical therapy during the rule-in phase, before RDN - Acceptable blood pressure control after medical treatment optimization - Identification of secondary causes of hypertension - Renal artery anatomy not suitable for RDN - Ejection fraction below 30% - Life expectancy below 1 year - Indication to cardiac surgery - Adenosine allergy - Pregnancy - Large necrotic area documented by either MRI, SPECT or combination of ECG signs + Echocardiographic images. - Hemodynamic instability - Refuse to sign informed consent - Age below 18 or above 80 Study Phase Inclusion Criteria: - Having coronary microvascular dysfunction documented by invasive functional assessment (IMR>25 and or CFR < 2) - Fulfilling all the rule-in phase inclusion criteria without any rule-in phase exclusion criteria Study Phase Exclusion Criteria: - Refuse to sign informed consent - Evidence of newly detected obstructive CAD on invasive coronary angiography performed 6 months after RDN

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Invasive Physiological Assessment of Coronary Circulation
After 2 months long rule-in phase required to exclude the unsuitable patients, study population will undergo RDN as indicated to treat resistant or difficult to control hypertension; 12 months after RDN, they will undergo invasive physiological study, comprehensive of Coronary Flow Reserve, Index of Microvascular Resistance, Mean Transit Time. These data will be then compared to the baseline ones obtained during the screening phase.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Aurelia Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Index of microvascular resistance (IMR) Matched comparison of IMR from baseline to 12 months after RDN 12 months
Secondary Coronary Flow Reserve (CFR) Matched comparison of CFR from baseline to 12 months after RDN 12 months
Secondary Mean transit time (TMN) Matched comparison of both resting and hyperemic TMN from baseline to 12 months after RDN 12 months
Secondary Systolic Blood Pressure (BP) on Ambulatory blood pressure monitoring (ABPM) Matched Comparison of Average Systolic Blood Pressure measured on 24 hour Ambulatory Blood Pressure Monitoring 12 Months
Secondary Diastolic BP on ABPM Matched Comparison of Average Systolic Blood Pressure measured on 24 hour Ambulatory Blood Pressure Monitoring 12 Months
Secondary Average BP on ABPM Matched Comparison of Average Mean Blood Pressure measured on 24 hour Ambulatory Blood Pressure Monitoring 12 Months
Secondary Time in Therapeutic BP Range Matched Comparison of total time spent with both systolic and diastolic BP within normality range measured on 24 hour Ambulatory Blood Pressure Monitoring 12 Months
Secondary BP Medication Burden Matched Comparison of Total Number of BP medication prescribed to the subject 12 Months
Secondary Mini-SAQ Score (Seattle Angina Questionnaire) Matched Comparison of Average Score on Mini Seattle Angina Questionnaire (SAQ) 12 Months
Secondary NTproBNP Matched Comparison of Average NTproBNP 12 Months
See also
  Status Clinical Trial Phase
Recruiting NCT05545059 - Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension Phase 3
Not yet recruiting NCT04388124 - VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION Phase 2
Withdrawn NCT01939392 - Rapid Renal Sympathetic Denervation for Resistant Hypertension II Phase 2/Phase 3
Recruiting NCT06228677 - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting NCT04213963 - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Recruiting NCT05563077 - Aerobic Exercise and Resistant Hypertension N/A
Recruiting NCT03758196 - Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension(RSDARH) N/A
Active, not recruiting NCT03179800 - CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™ N/A
Completed NCT04519658 - A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) Phase 2
Not yet recruiting NCT05426707 - Remote Ischemic Conditioning for the Treatment of Resistant Hypertension N/A
Not yet recruiting NCT05552300 - Superselective Adrenal Arterial Embolization for Resistant Hypertension N/A
Completed NCT04345198 - Adrenal Artery Ablation for Primary Aldosteronism With Resistant Hypertension N/A
Active, not recruiting NCT05562934 - An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. Phase 2
Recruiting NCT06034743 - A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension Phase 3
Withdrawn NCT02926495 - Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension. N/A
Active, not recruiting NCT02670681 - Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects N/A
Completed NCT02572024 - The Effect of BATon BP and Sympathetic Function in Resistant Hypertension (The Nordic BAT Study) N/A
Terminated NCT02295683 - Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry
Completed NCT02001350 - Carotid Ultrasound Study N/A
Recruiting NCT04331691 - Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension Phase 4